Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.63
-0.08 (-1.32%)
Sep 2, 2026, 1:15 PM EDT - Market open
Taysha Gene Therapies Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 455.41 | 319.77 | 139.04 | 143.94 | 87.88 | 149.1 |
Cash & Short-Term Investments | 455.41 | 319.77 | 139.04 | 143.94 | 87.88 | 149.1 |
Cash Growth | 45.61% | 129.99% | -3.41% | 63.79% | -41.06% | -40.66% |
Prepaid Expenses | 1.27 | 0.97 | 1.36 | 1.09 | 2.51 | 3.87 |
Restricted Cash | - | 0.45 | 0.45 | 0.45 | - | - |
Other Current Assets | 4.75 | 3.46 | 1.28 | 4.39 | 6.03 | 6.63 |
Total Current Assets | 461.43 | 324.65 | 142.13 | 149.87 | 96.42 | 159.6 |
Property, Plant & Equipment | 8.73 | 16.18 | 15.87 | 20.41 | 25.91 | 50.61 |
Other Long-Term Assets | 0.27 | 2.5 | 2.37 | 2.46 | 3.95 | 3.74 |
Total Assets | 470.43 | 343.32 | 160.36 | 172.73 | 126.28 | 213.96 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 9.16 | 6.28 | 3.59 | 6.37 | 10.95 | 21.76 |
Accrued Expenses | 15.25 | 17.62 | 9.59 | 9.46 | 14.04 | 25.85 |
Current Portion of Leases | 1.16 | 1.87 | 1.88 | 1.65 | 1.52 | - |
Current Unearned Revenue | - | - | 9.77 | 18.11 | 33.56 | - |
Other Current Liabilities | 0.4 | 0.8 | 1.4 | 1.18 | 2.73 | 4.14 |
Total Current Liabilities | 25.98 | 26.55 | 26.23 | 36.76 | 62.79 | 51.75 |
Long-Term Debt | 49.26 | 50.11 | 43.94 | 40.51 | 37.97 | 37.19 |
Long-Term Leases | 6.29 | 18.17 | 17.36 | 18.95 | 20.44 | 25.9 |
Other Long-Term Liabilities | 1.64 | 1.55 | 1.31 | 1.58 | 4.13 | 3.74 |
Total Liabilities | 83.17 | 96.38 | 88.84 | 97.79 | 125.33 | 118.57 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | - |
Additional Paid-In Capital | 1,187 | 958.43 | 677.86 | 587.94 | 402.39 | 331.03 |
Retained Earnings | -800.35 | -711.3 | -602.31 | -513.01 | -401.44 | -235.65 |
Comprehensive Income & Other | 0.77 | -0.19 | -4.03 | - | - | - |
Shareholders' Equity | 387.27 | 246.94 | 71.53 | 74.94 | 0.95 | 95.38 |
Total Liabilities & Equity | 470.43 | 343.32 | 160.36 | 172.73 | 126.28 | 213.96 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 56.71 | 70.14 | 63.18 | 61.11 | 59.93 | 63.09 |
Net Cash (Debt) | 398.69 | 249.62 | 75.86 | 82.83 | 27.95 | 86.01 |
Net Cash Growth | 57.59% | 229.08% | -8.42% | 196.34% | -67.50% | -65.77% |
Net Cash Per Share | 1.10 | 0.78 | 0.30 | 0.71 | 0.64 | 2.28 |
Filing Date Shares Outstanding | 325.83 | 287.27 | 205 | 187.02 | 63.47 | 38.47 |
Total Common Shares Outstanding | 325.3 | 285.05 | 204.94 | 186.96 | 63.21 | 38.47 |
Working Capital | 435.46 | 298.1 | 115.9 | 113.11 | 33.63 | 107.86 |
Book Value Per Share | 1.19 | 0.87 | 0.35 | 0.40 | 0.02 | 2.48 |
Tangible Book Value | 387.27 | 246.94 | 71.53 | 74.94 | 0.95 | 95.38 |
Tangible Book Value Per Share | 1.19 | 0.87 | 0.35 | 0.40 | 0.02 | 2.48 |
Machinery | 5.27 | 4.98 | 4.7 | 4.87 | 4.88 | 3.04 |
Construction In Progress | 0.24 | 4.29 | 4.25 | 6.82 | 9.63 | 46 |
Leasehold Improvements | 2.15 | 2.15 | 2.12 | 2.12 | 2.09 | 2.07 |